Regenxbio (RGNX) Other Operating Expenses (2014 - 2025)

Regenxbio's Other Operating Expenses history runs 12 years deep, the most recent figure standing at -$54000.0 for Q4 2025.

• In Q4 2025, Other Operating Expenses rose 93.52% year-over-year to -$54000.0; the TTM figure through Dec 2025 stood at -$179000.0 (up 79.31% YoY), while the FY2025 annual figure was -$179000.0, up 79.31% from the prior year.
• Other Operating Expenses was -$54000.0 for Q4 2025 at Regenxbio, up from -$65000.0 in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $19.2 million in Q3 2021 to a low of -$351.3 million in Q4 2023.
• Historically, Other Operating Expenses has averaged -$12.1 million across 5 years, with a median of $9500.0 in 2024.
• The sharpest annual moves came in 2021 and 2023: Other Operating Expenses jumped 20008.0% in 2021, then plunged 6603.44% in 2023.
• A 5-year view of Other Operating Expenses shows it stood at $15.0 million in 2021, then tumbled by 64.09% to $5.4 million in 2022, then slumped by 6603.44% to -$351.3 million in 2023, then soared by 99.76% to -$833000.0 in 2024, then soared by 93.52% to -$54000.0 in 2025.
• The last three Other Operating Expenses figures came in at -$54000.0 (Q4 2025), -$65000.0 (Q3 2025), and -$45000.0 (Q2 2025), per Business Quant data.